Update date: Jul 08, 2026 | 100 Pages | Report ID: HO-003682
Automated Breast Ultrasound Market
DMA IntelligenceAutomated Breast Ultrasound Market Opportunity by 2034 | In-Depth Report
Segments: Product (Automated Breast Ultrasound (ABUS)), End Use (Hospital, Diagnostics Imaging Laboratories, Others), By Region, And Segment Forecasts
$1082.0M
Market Size, 2025
$1169.6M
Market Estimate, 2026
$2017.6M
Market Forecast, 2033
8.1%
CAGR, 2026–2033
Automated Breast Ultrasound Market Size, Share & Key Insights
The Automated Breast Ultrasound Market size was valued at USD 1082.00 Million in 2025, and the market is projected to grow from USD 1169.64 Million in 2026 to USD 2017.59 Million by 2033, growing at a CAGR of 8.1% during the forecast period 2026–2033. The market saw distributed global demand in 2025.
Study Overview
 Study Period | 2021 - 2033 |
 Base Year | 2025 |
 Estimated Year | 2026 |
 Forecast Period | 2026-2033 |
 Historical Range | 2021-2025 |
| Units | USD Million |
 Coverage | Global | North America, Europe, Asia-Pacific, Latin America, Middle East & Africa |
 Deliverables | PDF + Excel Data Pack |
Major Market Players
Key Insights
- The Automated Breast Ultrasound market is projected to grow from USD 1082.00 Million in 2025 to USD 2015.84 Million by 2033, demonstrating a robust CAGR of 8.10% over the forecast period, driven by increasing breast cancer prevalence and dense breast tissue awareness.
- North America holds the largest market share in 2025 with USD 389.50 Million, while Asia Pacific is anticipated to be the fastest-growing regional market, exhibiting a high CAGR of 9.5% due to expanding healthcare infrastructure and rising screening initiatives.
- Automated Breast Ultrasound Systems constitute the dominant product segment, accounting for approximately 65% of the market in 2025, underscoring their critical role in advanced breast imaging and early cancer detection.
Market Definition and Strategic Context
The Automated Breast Ultrasound Market refers to the global industry encompassing the development, manufacturing, and distribution of advanced ultrasound systems specifically designed for comprehensive breast cancer screening, particularly in women with dense breast tissue. These systems offer an automated, standardized approach to whole-breast ultrasound imaging, complementing traditional mammography by providing superior detection rates for small, invasive cancers that may be obscured by dense tissue. The market's growth is driven by increasing awareness of dense breast tissue as a risk factor, technological advancements improving image quality and workflow, and a rising global incidence of breast cancer. The Automated Breast Ultrasound market size was valued at USD 1082.00 Million in 2025 and is projected for significant industry expansion, indicating a robust growth outlook and market forecast. Key benefits of ABUS systems include their non-ionizing radiation nature, ability to overcome limitations of mammography in dense breasts, and the potential for improved early detection, which is crucial for better patient outcomes. The market involves a complex interplay of medical device manufacturers, healthcare providers, diagnostic centers, and regulatory bodies, all contributing to its dynamic landscape. As healthcare systems globally prioritize early cancer detection and personalized medicine, the adoption of ABUS technology is expected to accelerate, further fueling market expansion. The strategic context of this market is shaped by ongoing innovation in AI-powered image analysis, integration with other diagnostic modalities, and efforts to make these advanced screening tools more accessible and cost-effective across diverse healthcare settings. This comprehensive approach to breast imaging enhances diagnostic confidence and supports informed clinical decision-making.
| Report Attribute | Details |
|---|---|
| Market size value in 2025 | USD 1,082.00 Million |
| Revenue forecast in 2033 | USD 2,017.59 Million |
| Growth rate | CAGR of 8.1% from 2025 to 2033 |
| Actual data | 2021 - 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD Million and CAGR from 2025 to 2033 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | Product, End Use |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
| Key companies profiled | GE HealthCare; Koninklijke Philips N.V; Siemens Healthcare Private Limited; CANON MEDICAL SYSTEMS CORPORATION; TELEMED Medical Systems srl; Hologic, Inc; SuperSonic Imagine; Lunit Inc; Delphinus Medical Technologies, Inc |
| Customization scope | Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Growth Catalysts & Market Constraints
The Automated Breast Ultrasound market is experiencing dynamic shifts, driven by a confluence of technological advancements, evolving healthcare policies, and a growing emphasis on early disease detection. These factors are shaping the Automated Breast Ultrasound market size and influencing its growth forecast, presenting both significant opportunities and persistent challenges. The industry's trajectory is increasingly tied to the ability of manufacturers to innovate and healthcare systems to adopt these sophisticated diagnostic tools. Understanding these underlying dynamics is crucial for stakeholders to navigate the market effectively and capitalize on emerging trends while mitigating potential risks. The continuous drive for improved diagnostic accuracy and patient comfort remains a central theme, propelling investment in research and development across the sector.
Growth Drivers
- Rising prevalence of breast cancer globally, coupled with an increasing awareness of the limitations of mammography in women with dense breast tissue, is significantly boosting the demand for supplemental screening technologies like Automated Breast Ultrasound. ABUS offers a non-invasive, radiation-free alternative that improves cancer detection rates in this high-risk population, leading to wider clinical adoption and driving market growth.
- Technological advancements in ABUS systems, such as enhanced image resolution, faster acquisition times, and the integration of artificial intelligence (AI) for automated lesion detection and analysis, are improving diagnostic accuracy and workflow efficiency. These innovations make ABUS a more attractive and practical option for healthcare providers, accelerating its integration into routine screening protocols.
Restraints
- The high initial capital investment required for Automated Breast Ultrasound systems, coupled with ongoing maintenance and operational costs, poses a significant restraint, particularly for smaller hospitals and diagnostic centers with limited budgets. This financial barrier can hinder widespread adoption, especially in developing regions where healthcare expenditure is constrained.
- A lack of standardized reimbursement policies and clear clinical guidelines for ABUS screening in some regions can create uncertainty for healthcare providers regarding financial viability and appropriate utilization. This regulatory ambiguity may deter investment and slow down the integration of ABUS into established breast screening programs.
Opportunities
- Expansion into emerging markets, particularly in Asia Pacific and Latin America, presents substantial growth opportunities due to rising healthcare expenditure, increasing breast cancer awareness, and improving healthcare infrastructure. These regions offer untapped patient populations and a growing demand for advanced diagnostic tools, creating fertile ground for ABUS market penetration.
- Integration of ABUS with advanced AI and machine learning algorithms offers a significant opportunity to enhance diagnostic accuracy, reduce inter-reader variability, and streamline radiologists' workflow. Further development in this area can lead to more efficient and precise breast cancer detection, making ABUS an indispensable tool in future breast imaging paradigms.
Challenges
- The need for specialized training and expertise for radiologists and sonographers to effectively operate and interpret ABUS images presents a challenge. The scarcity of adequately trained personnel can limit the widespread adoption and optimal utilization of these advanced systems, impacting diagnostic efficiency and market penetration.
- Achieving interoperability and seamless integration of ABUS systems with existing hospital information systems (HIS), picture archiving and communication systems (PACS), and other diagnostic modalities can be complex. This technical challenge can lead to workflow inefficiencies and data management issues, hindering the smooth adoption of ABUS technology in integrated healthcare networks.
Market Level Breakdown
The Automated Breast Ultrasound market is primarily segmented by Product and End Use, providing a detailed understanding of its diverse applications and operational domains. The Product segment encompasses Automated Breast Ultrasound Systems and Accessories, with the systems themselves forming the core of the market due to their direct involvement in imaging. These systems are critical for capturing high-resolution 3D images of the entire breast, particularly beneficial for women with dense breast tissue where mammography has limitations. Accessories, while smaller in market share, are essential for the functionality and maintenance of the systems, ensuring optimal performance and patient comfort. This segmentation helps in analyzing market trends related to technological advancements and product innovation.
The End Use segment categorizes the market based on the primary settings where ABUS systems are deployed, including Hospitals, Diagnostic Imaging Centers, and Others. Hospitals represent a significant share due to their comprehensive healthcare infrastructure, high patient volume, and integration of various diagnostic modalities. Diagnostic Imaging Centers, specializing in imaging services, also contribute substantially, driven by their focus on efficient and accurate diagnostic procedures. The 'Others' category includes specialized clinics and research institutions. This segmentation highlights the varying adoption rates and specific requirements of different healthcare settings, influencing market strategies for distribution, training, and service provision. Understanding these segments is crucial for stakeholders to tailor their offerings and penetrate key growth areas within the Automated Breast Ultrasound segmentation.
Automated Breast Ultrasound Segmentation Breakdown
- Product
- Automated Breast Ultrasound (ABUS)
- End Use
- Hospital
- Diagnostics Imaging Laboratories
- Others
Geographic Performance & Regional Trends
Geographically, the Automated Breast Ultrasound market exhibits significant regional disparities in adoption and growth. North America currently dominates the market, largely due to a well-established healthcare infrastructure, high awareness of breast cancer screening, and favorable reimbursement policies. However, Asia Pacific is emerging as the fastest-growing market, driven by increasing healthcare expenditure, a large patient pool, and improving access to advanced diagnostic technologies. This regional forecast underscores the shift in market dynamics, with emerging economies playing a crucial role in future expansion of the Automated Breast Ultrasound market growth. Factors such as government initiatives promoting early detection and growing medical tourism also contribute to the robust growth in these regions.
Regional Growth Drivers
- North America: High incidence of breast cancer, coupled with widespread awareness campaigns and established screening guidelines, drives the adoption of ABUS systems. Favorable reimbursement policies and a robust healthcare infrastructure in the United States and Canada facilitate the integration of these advanced technologies into routine clinical practice, ensuring continued market leadership.
- Europe: Increasing focus on early cancer detection and the presence of advanced medical research facilities across countries like Germany, the United Kingdom, and France fuel market expansion. Government initiatives aimed at improving breast cancer screening programs and a rising elderly population with higher risk factors contribute to sustained demand for ABUS.
- Asia Pacific: Rapidly developing healthcare infrastructure, increasing disposable incomes, and a growing emphasis on preventive healthcare in countries such as China, Japan, and India are significant drivers. A large population base with rising breast cancer incidence and improving access to modern diagnostic tools are propelling this region to be the fastest-growing market.
- Latin America: Modernization of healthcare facilities and increasing government investments in medical technologies contribute to market growth. Rising awareness about breast cancer screening and efforts to improve diagnostic capabilities in countries like Brazil and Mexico are fostering the adoption of ABUS systems, albeit from a lower base.
- Middle East & Africa: Upgrades in healthcare infrastructure, particularly in countries like Saudi Arabia and South Africa, and a growing number of diagnostic centers are driving demand. Increasing prevalence of breast cancer and initiatives to enhance early detection programs are creating opportunities for ABUS technology in this region.
The regional landscape for Automated Breast Ultrasound is characterized by mature markets like North America and Europe, which continue to innovate and refine existing practices, and rapidly expanding markets in Asia Pacific and Latin America, which are focused on increasing access and adoption. This dichotomy presents strategic implications for suppliers, who must adapt their market entry and expansion strategies to cater to diverse regulatory environments, economic conditions, and patient needs. The long-term forecast suggests a convergence in technological adoption, but regional nuances in healthcare delivery will continue to shape market trajectories.
Competitive Insights & Leading Companies
The competitive landscape of the Automated Breast Ultrasound market is moderately consolidated, with a few established global players holding significant market share alongside several niche and emerging companies. Key global players leverage their extensive distribution networks, strong brand recognition, and robust R&D capabilities to maintain their competitive edge. The market is characterized by intense competition in product innovation, particularly in enhancing image quality, reducing scan times, and integrating artificial intelligence for improved diagnostic accuracy. Pricing strategies vary, with premium pricing for advanced systems and competitive pricing for more accessible models. Regulatory approvals and certifications are critical competitive levers, ensuring market access and building physician trust. Regional players often focus on specific geographic markets, offering tailored solutions and localized support. The Automated Breast Ultrasound competitive landscape is also influenced by strategic collaborations and partnerships, which are increasingly common for expanding market reach and combining technological expertise.
Leading companies in the Automated Breast Ultrasound market are actively pursuing various strategies to strengthen their positions. Mergers and acquisitions are observed, enabling companies to expand their product portfolios and acquire complementary technologies or market access. Product launches featuring next-generation ABUS systems with enhanced features, such as advanced transducers and AI-powered analytics, are frequent. Companies are also focusing on geographical expansion, particularly into high-growth emerging markets, to tap into new customer bases. R&D investments are concentrated on improving system ergonomics, user interface, and integration with other diagnostic modalities to offer comprehensive breast care solutions. Differentiation is achieved through superior clinical performance, comprehensive service offerings, and strong relationships with healthcare providers. However, challenges such as margin pressure due to intense competition and the high cost of R&D, coupled with the need for continuous regulatory compliance, remain significant. Supply chain risks and the complexity of global logistics also pose operational hurdles for manufacturers in the Automated Breast Ultrasound market, impacting their ability to deliver products efficiently.
Automated Breast Ultrasound Key Companies
- GE HealthCare
- Koninklijke Philips N.V
- Siemens Healthcare Private Limited
- CANON MEDICAL SYSTEMS CORPORATION
- TELEMED Medical Systems srl
- Hologic, Inc
- SuperSonic Imagine
- Lunit Inc
- Delphinus Medical Technologies, Inc
Automated Breast Ultrasound Market Ecosystem
Ecosystem Participants
- Manufacturers — Develop, produce, and distribute Automated Breast Ultrasound (ABUS) systems and related accessories. They are at the forefront of innovation, focusing on enhancing imaging quality, reducing scan times, and improving user interface to meet evolving clinical needs and ensure regulatory compliance.
- These entities invest heavily in research and development to create cutting-edge technology, ensuring their systems meet stringent medical device regulations globally and address specific clinical challenges.
- Healthcare Providers — Hospitals, diagnostic centers, and clinics that acquire and utilize ABUS systems for breast cancer screening and diagnosis. They are key end-users, especially for women with dense breast tissue who require supplemental screening beyond mammography.
- Providers are responsible for integrating ABUS into existing imaging workflows, training technicians, and educating patients on the benefits of this advanced screening modality, ensuring optimal patient care and diagnostic accuracy.
- Regulatory Bodies — Government agencies and health authorities responsible for setting standards, approving medical devices, and ensuring patient safety and data privacy within the ABUS market. Their role is critical in governing market access and product development.
- These bodies establish guidelines for ABUS system performance, clinical efficacy, and cybersecurity, which significantly influence product design, market entry, and continued post-market surveillance, safeguarding public health.
- Research Institutions — Universities and research organizations conducting clinical trials and studies to validate ABUS efficacy, explore new applications, and contribute to technological advancements in breast imaging. They are crucial for evidence-based practice.
- Their published findings inform clinical practice, influence guideline development, and drive further investment into ABUS technology, often collaborating with manufacturers to bring innovative solutions to market.
- Software & AI Developers — Companies specializing in AI-driven image analysis software and data management solutions designed to enhance ABUS interpretation, workflow efficiency, and diagnostic accuracy. Their contributions are vital for optimizing clinical utility.
- These developers create algorithms for automated lesion detection, classification, and reporting, which significantly reduce radiologist workload, minimize inter-reader variability, and improve diagnostic consistency, thereby increasing the value proposition of ABUS.
Report Coverage & Key Deliverables
The report delivers a comprehensive analysis of the Automated Breast Ultrasound, combining quantitative data with qualitative insights to provide a holistic view of the market. It is meticulously structured to offer decision-makers actionable intelligence, covering historical performance, current market dynamics, and future growth projections. This extensive research provides a detailed understanding of market trends, competitive landscape, and key growth drivers and restraints impacting the industry. The scope encompasses a thorough examination of market segments, regional performance, and the strategic activities of leading companies. By integrating robust data analysis with expert commentary, the report aims to equip stakeholders with the necessary tools to formulate effective business strategies, identify lucrative investment opportunities, and navigate the evolving market environment with confidence and clarity. Its objective is to serve as an indispensable resource for strategic planning, market assessment, and competitive benchmarking within the Automated Breast Ultrasound sector.
Report Coverage
- Market Size Estimates (historical and forecast)
- This section provides precise market size figures for the Automated Breast Ultrasound market from 2021 to 2025 (historical) and projects forecasts up to 2033. The data is presented in USD Million, offering a clear quantitative overview based on rigorous analytical models and industry-validated methodologies, ensuring accuracy and reliability for strategic planning.
- Detailed Segmentation And Revenue Analysis
- The report offers an in-depth breakdown of the market by key segments such as product type (Automated Breast Ultrasound Systems, Accessories) and end-use (Hospitals, Diagnostic Imaging Centers, Others). Each segment's revenue contribution and growth trajectory are analyzed, providing insights into their respective market shares, growth rates, and future potential, enabling targeted business development strategies.
- Regional And Country-Level Insights
- This part of the report explores the Automated Breast Ultrasound market's performance across major geographical regions, including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. It further drills down into key countries within these regions, highlighting market maturity, specific growth drivers, regulatory landscapes, and competitive dynamics pertinent to each area, facilitating informed regional expansion decisions.
- Competitive Benchmarking Of Key Players
- A comprehensive analysis of the competitive landscape is provided, profiling leading companies such as GE HealthCare, Koninklijke Philips N.V, and Siemens Healthcare Private Limited. This includes their strategic initiatives, product portfolios, market positioning, and recent developments. The benchmarking offers insights into their strengths, weaknesses, and key differentiators, aiding in competitive strategy formulation and partnership identification.
- Customization Options Based on Specific Requirements
- The report offers flexible customization options to meet unique client needs. This includes modifications to the scope of analysis, addition or alteration of specific country or regional data, and deeper dives into particular segments. This ensures that the research directly addresses specific business questions, providing tailored insights beyond the standard report content and maximizing its value.
Recent Industry Insights
The Automated Breast Ultrasound industry has witnessed several pivotal developments over the past 12-18 months, reflecting a dynamic landscape driven by technological innovation and strategic collaborations. Key players are increasingly focusing on integrating artificial intelligence into ABUS systems to enhance diagnostic accuracy and workflow efficiency. Partnerships between medical device manufacturers and AI software developers are becoming common, aiming to create more intelligent and automated screening solutions. Regulatory bodies continue to play a crucial role, with new clearances and updated guidelines shaping market access and product features. These Automated Breast Ultrasound industry trends highlight a concerted effort across the ecosystem to improve early breast cancer detection, particularly for women with dense breasts, and to streamline clinical operations. The market is also seeing expansions into new geographic territories, indicating a global push for wider adoption.
Key Market Developments
- January 2024: GE HealthCare announced the acquisition of a European AI software company specializing in breast imaging analysis to enhance its ABUS portfolio.
- February 2024: Koninklijke Philips N.V. launched a new compact ABUS system designed for smaller clinics and diagnostic centers, expanding market accessibility.
- April 2024: Delphinus Medical Technologies, Inc. received FDA clearance for an updated version of its SoftVue 3D Whole Breast Ultrasound System, featuring improved image resolution.
- June 2024: Lunit Inc. partnered with a major Asian diagnostic imaging chain to integrate its AI-powered breast cancer detection software with existing ABUS platforms across South Korea and Japan.
- August 2024: Siemens Healthcare Private Limited initiated a clinical trial in India to evaluate the effectiveness of its ABUS technology in screening women with extremely dense breasts.
Analyst Opinion
The Automated Breast Ultrasound market presents a highly attractive investment proposition, primarily driven by the unmet need for effective breast cancer screening in women with dense breast tissue. The market's competitive intensity is moderately consolidated, with key players continually innovating to gain a larger share through technological advancements and strategic partnerships. Demand for ABUS systems is robust and is expected to grow steadily, fueled by increasing global breast cancer incidence and a heightened focus on early detection. The supply side is responding with enhanced product offerings, but challenges persist in terms of high capital costs and the need for specialized training. Overall, the Automated Breast Ultrasound market outlook remains positive, indicating significant opportunities for both established players and new entrants focusing on cost-effectiveness and accessibility.
Looking ahead, the long-term outlook for the Automated Breast Ultrasound market is exceptionally promising, with continuous innovation in artificial intelligence and machine learning poised to revolutionize diagnostic capabilities. The integration of AI for automated image analysis, lesion detection, and risk stratification will be a critical differentiator, streamlining workflows and improving diagnostic accuracy. However, key risk factors include the slow pace of regulatory approvals in some regions, reimbursement uncertainties, and the need for extensive clinical validation to demonstrate long-term efficacy and cost-effectiveness. Strategic implications suggest that companies investing in R&D for AI-powered solutions, expanding into underserved emerging markets, and focusing on comprehensive training programs will be best positioned to capitalize on the sustained growth trajectory of this vital medical imaging sector.